| Title | Dynamics of T follicular helper cells in patients with rheumatic diseases and subsequent antibody responses in a three-dose immunization regimen of CoronaVac |
| Authors | Zhou, Xingyu Wang, Yifan Huang, Bo Feng, Ruiling Zhou, Xinyao Li, Chun Zhang, Xia Shao, Miao Gan, Yuzhou Jin, Yuebo An, Yuan Xiao, Xian Wang, Shiyang Liu, Qinghong Cheng, Gong Zhu, Fengyunzhi Zhang, Kai Wang, Naidi Xing, Xiaoyan Li, Ru Li, Yuhui Liu, Yisi Lu, Dan Sun, Xiaolin Li, Zhanguo Liu, Yudong He, Jing |
| Affiliation | Peking Univ Peoples Hosp, Dept Rheumatol & Immunol, Beijing Key Lab Rheumatism Mech & Immune Diag BZ0, Beijing, Peoples R China Chinese Acad Med Sci, Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China Capital Med Univ, Beijing Youan Hosp, Dept Liver Dis Ctr 1, Beijing, Peoples R China Peking Univ, Sch Basic Med Sci, Inst Syst Biomed, Hlth Sci Ctr, Beijing, Peoples R China Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing, Peoples R China Chinese Acad Med Sci, Key Lab Geriatr, Beijing Inst Geriatr,Inst Geriatr Med, Beijing Hosp,Natl Ctr Gerontol,Natl Hlth Commiss, 1 DaHua Rd, Beijing 100730, Peoples R China |
| Keywords | COVID-19 |
| Issue Date | Sep-2022 |
| Publisher | IMMUNOLOGY |
| Abstract | Given increased acceptance of the CoronaVac, there is an unmet need to assess the safety and immunogenic changes of CoronaVac in patients with rheumatic diseases (RD). Here we comprehensively analysed humoral and cellular responses in patient with RD after a three-dose immunization regimen of CoronaVac. RD patients with stable condition and/or low disease activity (n = 40) or healthy controls (n = 40) were assigned in a 1:1 ratio to receive CoronaVac (Sinovac). The prevalence of anti-receptor binding domain (RBD) antibodies and neutralizing antibodies was similar between healthy control (HC) and RD patients after the second and the third vaccination. However, the titers of anti-RBD IgG and neutralizing antibodies were significantly lower in RD patients compared to HCs (p < 0.05), which was associated with an impaired T follicular helper (Tfh) cell response. Among RD patients, those who generated an antibody response displayed a significantly higher Tfh cells compared to those who failed after the first and the second vaccination (p < 0.05). Interestingly, subjects with a negative serological response displayed a similar Tfh memory response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived peptides as their anti-RBD IgG positive counterpart, and all (4/4) of the non-responders in HCs, and 62.5% (5/8) of the non-responders in patients with RD displayed a positive serological response following the third dose. No serious adverse events were observed. In conclusion, our findings support SARS-CoV-2 vaccination in patients with RD with stable and/or low disease activity. The impaired ability in generating vaccine-specific antibodies in patients with RD was associated with a reduction in Tfh cells induction. The window of vaccination times still needs to be explored in future studies. Clinical trial registration: This trial was registered with ChiCTR2100049138. |
| URI | http://hdl.handle.net/20.500.11897/669123 |
| ISSN | 0019-2805 |
| DOI | 10.1111/imm.13572 |
| Indexed | SCI(E) |
| Appears in Collections: | 人民医院 基础医学院 药学院 天然药物与仿生药物国家重点实验室 |
